EP1576010A4 - Compositions et procedes therapeutiques contre les cancers caracterises par l'expression de l'antigene mn/ca ix associe aux tumeurs - Google Patents

Compositions et procedes therapeutiques contre les cancers caracterises par l'expression de l'antigene mn/ca ix associe aux tumeurs

Info

Publication number
EP1576010A4
EP1576010A4 EP03749129A EP03749129A EP1576010A4 EP 1576010 A4 EP1576010 A4 EP 1576010A4 EP 03749129 A EP03749129 A EP 03749129A EP 03749129 A EP03749129 A EP 03749129A EP 1576010 A4 EP1576010 A4 EP 1576010A4
Authority
EP
European Patent Office
Prior art keywords
tumor
therapy
expression
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03749129A
Other languages
German (de)
English (en)
Other versions
EP1576010A2 (fr
Inventor
Justin Wong
Jill Winter
Guita Lalehzadeh
Robert Warne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of EP1576010A2 publication Critical patent/EP1576010A2/fr
Publication of EP1576010A4 publication Critical patent/EP1576010A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP03749129A 2002-08-23 2003-08-25 Compositions et procedes therapeutiques contre les cancers caracterises par l'expression de l'antigene mn/ca ix associe aux tumeurs Withdrawn EP1576010A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40557702P 2002-08-23 2002-08-23
US405577P 2002-08-23
US64693403A 2003-08-22 2003-08-22
US646934 2003-08-22
PCT/US2003/026612 WO2004017923A2 (fr) 2002-08-23 2003-08-25 Compositions et procedes therapeutiques contre les cancers caracterises par l'expression de l'antigene mn/ca ix associe aux tumeurs

Publications (2)

Publication Number Publication Date
EP1576010A2 EP1576010A2 (fr) 2005-09-21
EP1576010A4 true EP1576010A4 (fr) 2006-12-27

Family

ID=31949897

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03749129A Withdrawn EP1576010A4 (fr) 2002-08-23 2003-08-25 Compositions et procedes therapeutiques contre les cancers caracterises par l'expression de l'antigene mn/ca ix associe aux tumeurs

Country Status (5)

Country Link
EP (1) EP1576010A4 (fr)
JP (1) JP2005536220A (fr)
AU (1) AU2003268180A1 (fr)
CA (1) CA2496572A1 (fr)
WO (1) WO2004017923A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2477163C (fr) 2002-02-21 2010-07-27 Institute Of Virology Forme soluble d'anhydrase carbonique ix- (s-ca-ix), dosage servant a detecter la co-expression de s-ca ix et ca ix's en utilisant le her-2/neu/c-erbb-2, et des anticorps monoclonales ca ix-specifique a des epitopes non-immunodominants
US7833734B2 (en) 2002-11-26 2010-11-16 Institute Of Virology Of The Slovak Academy Of Sciences CA IX-specific inhibitors
DOP2006000277A (es) * 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
WO2008091798A2 (fr) * 2007-01-22 2008-07-31 Xencor, Inc. Anticorps de ca9 optimises et methodes d'utilisation associees
EP2234608A2 (fr) * 2007-12-11 2010-10-06 Viamet Pharmaceuticals, Inc. Inhibiteurs de métalloenzymes utilisant des fractions de liaison à un métal en combinaison avec des fractions de ciblage
WO2020226612A1 (fr) * 2019-05-06 2020-11-12 Navi Bio-Therapeutics, Llc Anticorps anti-anhydrase carbonique ix

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024913A2 (fr) * 1998-10-23 2000-05-04 Bayer Corporation Gene et proteine mn

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955075A (en) * 1992-03-11 1999-09-21 Institute Of Virology, Slovak Academy Of Sciences Method of inhibiting tumor growth using antibodies to MN protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024913A2 (fr) * 1998-10-23 2000-05-04 Bayer Corporation Gene et proteine mn

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. SAARNIO ET EL.: "Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation.", AMERICAN JOURNAL OF PATHOLOGY, vol. 153, no. 1, 1998, pages 279 - 285 *

Also Published As

Publication number Publication date
WO2004017923A3 (fr) 2005-07-14
CA2496572A1 (fr) 2004-03-04
AU2003268180A8 (en) 2004-03-11
AU2003268180A1 (en) 2004-03-11
EP1576010A2 (fr) 2005-09-21
JP2005536220A (ja) 2005-12-02
WO2004017923A2 (fr) 2004-03-04

Similar Documents

Publication Publication Date Title
AU2003302892A8 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EP1515982A4 (fr) Methodes et compositions pour la therapie et le diagnostic du cancer de la prostate
EP1571968A4 (fr) Compositions et methodes permettant de diagnostiquer et de traiter une tumeur
EP1589933A4 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
AU2003293194A8 (en) Compositions and methods for treating prostate cancer
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
EP1571968A3 (fr) Compositions et methodes permettant de diagnostiquer et de traiter une tumeur
EP1572091A4 (fr) Compositions et methodes de diagnostic et de traitement de tumeurs
EP1578996A4 (fr) Compositions et methodes pour diagnostiquer et traiter des tumeurs
EP1553912A4 (fr) Compositions et methodes pour le diagnostic et pour le traitement d'une tumeur
EP1572091A3 (fr) Compositions et methodes de diagnostic et de traitement de tumeurs
AU2003224076A1 (en) Antibody combination useful for tumor therapy
EP1575571A4 (fr) Compositions et methodes de diagnostic et de traitement d'une tumeur
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
EP1551388A4 (fr) Composes utiles dans le traitement du cancer, compositions et procedes correspondants
EP1349485A4 (fr) Compositions et methodes destinees a la therapie et au diagnostic du cancer de l'ovaire
PL368035A1 (en) Compositions and methods for the treatment of cancer
AU3483001A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2003268180A8 (en) Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
AU2003219160A1 (en) Methods and compositions for the treatment of cancer
AU2003230849A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2001249493A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
EP1587405A4 (fr) Nouvelles compositions et procedes de traitement du cancer
AU2003298708A8 (en) Gpc99 and gpc99a: methods and compositions for treating cancer
AU2004281077A1 (en) Methods and agents for the treatment of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050315

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20061128

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

17Q First examination report despatched

Effective date: 20090602

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20091123